The hardest biotech validation challenges are rarely scientific. They are structural: validation sits apart from quality, evidence lives in documents instead of data, rules differ by jurisdiction, and new computerized and AI systems arrive faster than teams can qualify them. This article walks through each challenge, what regulators actually say about it, and what a QA or validation lead can do this quarter.

TL;DR

  • Validation is now a lifecycle, not a one-time event. The FDA's process validation model runs from design through qualification to continued verification.
  • Siloed validation teams, paper-style digital tools and manual documentation extend cycles and weaken audit trails.
  • Computerized system validation is where inspectors find data integrity gaps, and AI adds non-deterministic behavior to the mix.
  • Requirements differ by country, so a single global validation approach needs a risk-based core and local overlays.
  • Automation helps when every record is checked against ALCOA+ as it is written and human signatures stay authoritative.

Table of Contents

Why validation is harder in biotech than in classic pharma

Biologics are made by living systems. Variability is part of the process, so "validated" cannot mean "identical every time." It has to mean "we understand our sources of variation and keep them in control." That is a harder claim to prove and a harder one to document.

The FDA's process validation guidance makes this explicit. It describes a three-stage lifecycle: Stage 1 Process Design, Stage 2 Process Qualification, and Stage 3 Continued Process Verification. The guidance expects manufacturers to identify sources of variation and maintain a state of control throughout commercial manufacture. A passing set of three PPQ batches does not end the work; it starts the monitoring phase.

Three stages of the process validation lifecycle

The same principle applies to the evidence behind inputs. Reagents, standards and reference materials are only as defensible as the proof attached to them, which is why teams are increasingly strict about peptide purity verification that moves from a supplier's claim to documented evidence. Validation challenges begin the moment evidence is assumed instead of shown.

Challenge 1: Siloed validation and quality functions

In many organizations, validation reports into engineering or operations while quality owns the procedures, deviations and CAPA. The two meet at document review, which is late and expensive.

Nina Ricciardelli, writing in Pharmaceutical Engineering, notes that siloed structures lead to inefficiency, misaligned compliance efforts and longer validation cycles. She argues that moving from paper-based or legacy digital systems to a data-centric strategy is what breaks the pattern.

What this looks like day to day:

  • A change control is raised, but nobody tells validation until the protocol is already stale.
  • Deviations found during execution are tracked in one system and the validation report in another.
  • The traceability matrix is rebuilt by hand before every inspection, the classic fire drill before an audit.

What helps: assign one owner for the validation lifecycle across URS, risk assessment, testing and release, and connect it to your QMS so that change, deviation and CAPA records feed validation automatically. Our guide to QMS integration for validation covers where the authoring time goes and how integration removes it.

Challenge 2: Qualification versus validation confusion

Teams still mix up equipment qualification (DQ, IQ, OQ, PQ) with process and system validation. The result is duplicated testing in some places and gaps in others. Qualification shows that a piece of equipment or a system is fit for its intended use; validation shows that the process or the system, as used, consistently delivers the required outcome.

If your organization cannot answer "which test proves which requirement" in one view, you have this problem. Our practical guide to qualification versus validation lays out the boundary and the documents each side owes you.

Challenge 3: Continued process verification at scale

Stage 3 is where many biotech programs fall behind. Data must be collected, trended and reviewed across batches, sites and sometimes contract manufacturers. The FDA guidance asks that lifecycle studies be documented and well archived so scientific knowledge is captured and the validation program becomes more effective and efficient.

The ICH Q8/Q9/Q10 implementation points add useful flexibility: control strategies can be refined for commercial manufacture as knowledge is gained, and risk-based approaches can be used to assess their suitability across scales. Used well, that means you do not have to re-validate everything; you have to show why a change is or is not significant.

Practical moves:

  1. Define which parameters and attributes are critical using a documented risk assessment.
  2. Set trending rules and alert limits before commercial launch, not after the first excursion.
  3. Link every excursion to a deviation and, where needed, a CAPA, so the loop closes in a single record chain.

Challenge 4: Computerized system validation and data integrity

Most modern biotech operations run on computerized systems: LIMS, MES, CMMS, chromatography data systems, environmental monitoring. Each one needs validation, and each one creates records that inspectors will read.

The WHO's guideline on data integrity identifies inadequate human practices, poorly defined procedures, resource constraints and inappropriate validation of computerized systems as common causes of data integrity observations during inspections. The EMA's notice to sponsors is blunt about the consequence for clinical data: failing to document or demonstrate the validated state of a system is a high risk to data reliability and could prevent the data being used in submissions. The same notice says sponsors remain ultimately responsible, and that audit trails, security systems and authorized user lists must be maintained.

In the US, the baseline is 21 CFR Part 11, which applies to records in electronic form created, modified, maintained, archived, retrieved or transmitted under agency record requirements. If your system holds such records, audit trail and signature controls are not optional extras.

Three recurring weak points:

  • Audit trails that exist but are never reviewed. A trail nobody reads is not a control.
  • Validation of a system in isolation. The interfaces, the user roles and the data flows between systems are where integrity breaks.
  • Supplier documentation accepted without challenge. The ISPE GAMP community stresses leveraging supplier knowledge and documentation together with critical thinking from experienced SMEs, which means using it, but not blindly.

For concrete designs, see our data integrity by design playbook, the data integrity compliance playbook, and the seven elements of GxP audit trail design. For a system-specific example, the LIMS validation walkthrough shows how ALCOA+ proof is assembled under a risk-based CSA approach, and the CMMS validation guide does the same for maintenance systems.

Challenge 5: Digital tools that behave like paper

Many teams have already moved to electronic validation tools and still feel no relief. The reason, according to ISPE's 2025 white paper on digital validation, is that digital tools often replicate rigid, paper-based structures, limit integration and still need manual intervention for updates.

A PDF in a workflow is still a PDF. If a requirement changes and someone must manually find and edit every dependent test, you have digitized the paper, not the process.

A useful test: change one requirement in your URS. How many places must a human update? If the answer is more than one, the traceability is manual. Our paperless validation guide describes what a data-centric alternative looks like in practice.

Challenge 6: AI in and around the validated state

Two separate questions land on the validation lead's desk. First, how do we validate AI used in GxP processes? Second, how do we use AI to do validation work?

On the first, the EMA's 2024 reflection paper says developers must proactively manage risks from AI and ML tools throughout their lifecycle, noting that malfunction can have anything from minimal to life-threatening impact depending on the context of use. It also advises early regulatory interaction where an AI system could, even potentially, affect a product's benefit-risk balance.

The practical difficulties are well known: outputs that are not deterministic, models that change, limited explainability, dependence on data quality and rules that are still evolving. The answer is the same discipline you already apply elsewhere: define intended use, classify risk, test against acceptance criteria, control change, and keep a human accountable.

On the second question, the bar is the same. An AI that drafts a protocol does not own the protocol. A person reviews, edits and signs, and the record shows what was machine-drafted and what was human-approved.

Challenge 6: AI in and around the validated state

Challenge 7: Different rules in different jurisdictions

If you sell or manufacture in more than one region, you validate against more than one rulebook. A 2025 IFPMA and Clarivate study of 22 countries found that risk-based categorization of post-approval changes is common, but requirements and timelines for biotherapeutic products vary. A change that is a notification in one market can be a prior-approval filing in another, and your validation evidence must support whichever applies.

A working reference set for a US-headquartered biotech with global ambitions:

TopicUS referenceEU / international reference
Process validationFDA 2011 process validation guidanceEU GMP Annex 15 (qualification and validation)
Electronic records and signatures21 CFR Part 11EU GMP Annex 11 (computerized systems)
Data integrityFDA guidance and Part 11WHO data integrity guideline
Risk managementICH Q9ICH Q8/Q9/Q10 points to consider
AI in the medicines lifecycleAgency guidance still developingEMA reflection paper
Clinical computerized systemsICH E6 and Part 11EMA notice to sponsors

Build one risk-based validation core that satisfies the strictest requirement you face, then add local overlays. Rewriting the whole package per market is the quiet tax that drains validation budgets.

Challenge 8: Time, headcount and the authoring burden

Behind every challenge above is the same constraint: documents. URS, FS, risk assessments, IQ/OQ/PQ protocols, execution evidence, deviations, summary reports. Skilled engineers spend most of their time formatting, cross-referencing and checking instead of thinking about risk.

The lever is not cutting corners. It is moving the checking to the moment the record is created, and using risk to decide where depth is needed. Sterilization and cleaning programs show the point clearly: a lifecycle approach to sterilization validation and a three-phase risk-based cleaning validation strategy both concentrate effort where patient risk is highest.

How we think about this

We build validation software for regulated life sciences teams, and the pattern we see is consistent. Teams are not short on good intentions. They are short on time, and the evidence trail suffers when time runs out.

Our view rests on four commitments:

  • Evidence is checked when it is written. Every record should be ALCOA+ checked at write-time and again at review-time, so gaps surface in the week they occur, not in the week of the inspection.
  • Humans stay authoritative. Agents can draft, cross-check and flag. Signatures belong to people.
  • The platform lives inside your perimeter. Validated private deployment, with no data leaving your infrastructure, customer-managed encryption and freedom to choose the language model, is what lets QA and InfoSec both sign off.
  • Traceability should be live. A matrix that updates when the requirement changes is a different category of control from one rebuilt by hand.

So the real question is not whether to automate validation. It is whether your automation makes the evidence more defensible or just faster to produce. Only the first is worth buying.

— Matt

Where Qualitum fits

If these challenges sound familiar, Validate·AI and Operate·AI on the Qualitum platform are built for them: agent-authored validation lifecycle documents from URS through PQ, a live traceability matrix, deviation and CAPA handling, and integration with your existing QMS. Teams typically start with a paid pilot on one system so results can be judged against their own templates and standards before wider rollout. You can start with a pilot to see how it works on your documents.

Qualitum

For a closer look at individual capabilities, see how the drafting agent produces IQ/OQ/PQ and test specifications in your templates, or how executed protocol and evidence review catches problems before QA sees them.

A practical 90-day plan

You do not need a program overhaul to make progress. Start here:

  1. Days 1 to 30: map the lifecycle. List your GxP computerized systems and critical processes, and note for each the last validation date, its owner and where its evidence lives.
  2. Days 31 to 60: find the manual joins. Pick two systems and trace one requirement through to test evidence. Count the manual steps and the places where it could break.
  3. Days 61 to 90: fix one loop. Connect change control to validation impact assessment for a single system, or introduce write-time ALCOA+ checks on one document type. Measure authoring time before and after.

Small, measured changes give you a defensible story for the next inspection and a business case for the next investment.

FAQ

What is the biggest validation challenge for biotech companies?

For most teams it is keeping evidence current across a lifecycle rather than producing it once. Process validation, computerized system validation and change control all keep generating work after go-live. Siloed teams and manual documentation make that ongoing work slow and error-prone.

How is biotech process validation different from small-molecule validation?

The principles are the same, but biologics carry more inherent variability because they come from living systems. That makes process understanding and continued process verification central, as the FDA's three-stage lifecycle model reflects. Teams need stronger trending and a clear link between variation and control strategy.

Does AI used in validation need to be validated?

If an AI tool affects GxP records or decisions, you should treat it as a computerized system within a risk-based approach. Define its intended use, test it against acceptance criteria and control changes to it. Keep a qualified person responsible for review and signature, and consult the EMA's reflection paper for its lifecycle expectations.

How do we stay audit-ready without adding headcount?

Move checks to the moment of record creation, connect validation to your QMS so changes propagate, and keep traceability live instead of rebuilt before audits. Automation can carry the authoring load, provided humans stay the signing authority and the audit trail is complete.

Which regulations matter most for a US biotech selling globally?

Start with the FDA's process validation guidance and 21 CFR Part 11, then map EU GMP Annexes 11 and 15 and ICH Q8 to Q10 on top. Use a risk-based core and local overlays, and confirm current requirements with each regulator's official pages.

Sources

FAQ

What is the biggest validation challenge for biotech companies?

For most teams it is keeping evidence current across a lifecycle rather than producing it once. Process validation, computerized system validation and change control all keep generating work after go-live. Siloed teams and manual documentation make that ongoing work slow and error-prone.

How is biotech process validation different from small-molecule validation?

The principles are the same, but biologics carry more inherent variability because they come from living systems. That makes process understanding and continued process verification central, as the FDA's three-stage lifecycle model reflects. Teams need stronger trending and a clear link between variation and control strategy.

Does AI used in validation need to be validated?

If an AI tool affects GxP records or decisions, you should treat it as a computerized system within a risk-based approach. Define its intended use, test it against acceptance criteria and control changes to it. Keep a qualified person responsible for review and signature, and consult the EMA's reflection paper for its lifecycle expectations.

How do we stay audit-ready without adding headcount?

Move checks to the moment of record creation, connect validation to your QMS so changes propagate, and keep traceability live instead of rebuilt before audits. Automation can carry the authoring load, provided humans stay the signing authority and the audit trail is complete.

Which regulations matter most for a US biotech selling globally?

Start with the FDA's process validation guidance and 21 CFR Part 11, then map EU GMP Annexes 11 and 15 and ICH Q8 to Q10 on top. Use a risk-based core and local overlays, and confirm current requirements with each regulator's official pages.